247569-44-4

Upstream product

• 38185-19-2 4-(methylthio)benzyl bromide 
• 1074-82-4 potassium phtalimide 
• 3446-90-0 4-(methylthio)benzyl alcohol 
• 85-44-9 phthalic anhydride 
• 83171-39-5 4-(methylthio)benzylamine 
• 136918-14-4 phthalimide 
• 2446-83-5 diisopropyl (E)-azodicarboxylate 
• 100-51-6 benzyl alcohol 

Downstream Products

• 1570080-82-8 [[4-(aminomethyl)phenyl]-methyl-oxo-λ⁶-sulfanylidene]cyanamide 
• 1570082-23-3 [[4-[(1,3-dioxoisoindolin-2-yl)methyl]phenyl]-methyl-oxo-λ⁶-sulfanylidene]cyanamide 
• 15996-74-4 4-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]benzonitrile 
• 1570082-20-0 [[4-[(1,3-dioxoisoindolin-2-yl)methyl]phenyl]-methyl-λ⁴-sulfanylidene]cyanamide 
• 1570075-93-2 5-(3-(difluoromethyl)phenyl)-1-isopropyl-6-methyl-4-oxo-1,4-dihydropyridine-3-carboxylic acid 4-(N-cyano-S-(methyl)sulfonimidoyl)benzylamide 
• 1570078-91-9 6-methyl-1-(2-methyl-2H-pyrazol-3-yl)-4-oxo-1,4-dihydropyridine-3-carboxylic acid 4-(N-cyano-S-(methyl)sulfonimidoyl)benzylamide 
• 1570078-23-7 5-bromo-6-methyl-1-(2-methyl-2H-pyrazol-3-yl)-4-oxo-1,4-dihydropyridine-3-carboxylic acid 4-(N-cyano-S-(methyl)sulfonimidoyl)benzylamide 
• 1570077-45-0 5-bromo-1-cyclobutyl-6-methyl-4-oxo-1,4-dihydropyridine-3-carboxylic acid 4-(N-cyano-S-(methyl)sulfonimidoyl)benzylamide 
• 1570077-35-8 5-bromo-1-ethyl-6-methyl-4-oxo-1,4-dihydropyridine-3-carboxylic acid 4-(N-cyano-S-(methyl)sulfonimidoyl)benzylamide 
• 1570077-28-9 5-bromo-1-isopropyl-6-methyl-4-oxo-1,4-dihydropyridine-3-carboxylic acid 4-(N-cyano-S-(methyl)sulfonimidoyl)benzylamide 

Relevant academic research and scientific papers

Nickel-Catalyzed Reversible Functional Group Metathesis between Aryl Nitriles and Aryl Thioethers

We describe a new functional group metathesis between aryl nitriles and aryl thioethers. The catalytic system nickel/dcype is essential to achieve this fully reversible transformation in good to excellent yields. Furthermore, the cyanide- and thiol-free reaction shows high functional group tolerance and great efficiency for the late-stage derivatization of commercial molecules. Finally, synthetic applications demonstrate its versatility and utility in multistep synthesis.

SUBSTITUTED PYRIDONES AND PYRAZINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY

Substituted 2-pyridones and pyrazinones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other auto-immune and allergic disorders, allograft rejection and oncological diseases.

SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY

This invention relates to substituted 4-pyridones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other auto-immune and allergic disorders, allograft rejection, and oncological diseases.

SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY

This invention relates to substituted 4-pyridones of formula (1) and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other auto-immune and allergic disorders, allograft rejection, and oncological diseases.

Novel thiourea derivatives and the pharmaceutical compositions containing the same

The present invention relates to novel thiourca derivatives as a modulator for vanilloid receptor (VR) and the phar- maceutical compositions containing the same. As diseases associated with the activity of vanilloid receptor, pain acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflam- matory bowel disease and inflammatory diseases can be enumerated. The present invention provides a pharmaceutical composition for prevention or treatment of these diseases.

Anthranilic acid derivatives as inhibitors of the cGMP-phosphodiesterase

Compounds of formula (I) STR1where R 1 is hydrogen; R 2 is nitro, cyano or halo(lower)alkyl; R 3 is phenyl substituted with one or more substituents selected from halogen, cyano and lower alkoxy; A is a lower alkylene group; R 4 is a group CR 6 R 7 R 8 wherein R 6 and R 7 form, together with the carbon atom to which they are attached a cycloalkyl group optionally substituted with hydroxy, lower alkoxy or a lower alkanoylamino; and R 8 is hydrogen; its prodrug and a salt thereof.